MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced on Wednesday that Canadian-produced GMP Beacon Medical cannabis oil and inhalation cartridges have launched in the Australian medical marijuana market.
The cannabis oil portfolio features a high CBD Isolate (THC-free) oil, a balanced oil and a THC dominant full spectrum oil made with Beacon's popular medical flower strains.
The inhalation cartridges include flavor-forward options popular with patients in the Canadian market and strain-specific full-spectrum cartridges that utilize flower varieties already favored by Beacon Medical patients.
With Beacon Medical's Pink Kush and GSC products available in flower, oil and inhalation formats, the company provides physicians and patients with three delivery methods to consume the same full spectrum strains.
Deliveries of inhalation cartridges to patients kicked off this week, and cannabis oils are scheduled to ship from Canada this week as well, the Toronto, Canada-based company said in a press release.
MediPharm holds an Australian GMP license from the Therapeutic Goods Administration (TGA), complemented by its GMP status from Health Canada (Drug Establishment License) and the US FDA.
In July 2023, the TGA revised import and medical cannabis regulations, requiring all products to meet cGMP standards.
What's Next
Beacon Medical Australia plans to educate and collect feedback on these products from physicians and patients with the help of its recently expanded medical scientific liaison field team.
This allows MediPharm Labs further access to the Australian medical cannabis market.
Want to watch our Cannabis Capital Conference live? For existing subscribers you can get direct access through our research platform. For new users, you can get instant access here!
MEDIF Price Action
MediPharm's shares traded 0.2686% higher at $0.056 per share at the time of writing on Wednesday morning.
Related News
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- Could Medical Cannabis Be The Answer For Fibromyalgia? Here's What New Study Found
- Cannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The Details
- MediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA Status
Photo: Courtesy of Kimzy Nanney on Unsplash